Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2016 | Pages:
40 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) - Pipeline Review, H2 2016', provides in depth analysis on Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) targeted pipeline therapeutics. The report provides comprehensive information on the Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) - The report reviews Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) targeted therapeutics and enlists all their major and minor projects - The report assesses Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) Overview 6 Midkine (MDK) or neurite growth-promoting factor 2 is a protein encoded by the MDK gene. It binds to anaplastic lymphoma kinase which induces ALK activation and subsequent phosphorylation of the insulin receptor substrate, activation of mitogen-activated protein kinase and PI3-kinase and the induction of cell proliferation. It is involved in neointima formation after arterial injury and early fetal adrenal gland development. 6 Therapeutics Development 7 Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) - Products under Development by Stage of Development 7 Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) - Products under Development by Therapy Area 8 Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) - Products under Development by Indication 9 Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) - Pipeline Products Glance 10 Early Stage Products 10 Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) - Products under Development by Companies 11 Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) - Products under Development by Universities/Institutes 13 Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) - Therapeutics Assessment 15 Assessment by Monotherapy/Combination Products 15 Assessment by Mechanism of Action 16 Assessment by Molecule Type 17 Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) - Companies Involved in Therapeutics Development 19 Cellmid Limited 19 Ribomic Inc. 20 Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) - Drug Profiles 21 Antisense RNAi Oligonucleotides to Inhibit Midkine for Cardiovascular Diseases - Drug Profile 21 Product Description 21 Mechanism Of Action 21 R&D Progress 21 CAB-101 - Drug Profile 22 Product Description 22 Mechanism Of Action 22 R&D Progress 22 CAB-102 - Drug Profile 23 Product Description 23 Mechanism Of Action 23 R&D Progress 23 iMDK - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 IP-13 - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 IP-9 - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 Monoclonal Antibody to Inhibit Midkine for Bone Fractures - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 RBM-001 - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 Small Molecule to Inhibit Midkine for Lung Cancer - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) - Dormant Projects 32 Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) - Featured News & Press Releases 33 Aug 09, 2016: Cellmid: New Publication For Cellmid Midkine Antibody 33 Jun 24, 2016: Cellmid: New Publication And Patent Application For Midkine Antibody 33 Jun 23, 2015: Cellmid Collaboration To Treat Brain Cancer 35 Jun 15, 2015: Cellmid'S Humanized Midkine Antibody Drug Is Safe In Toxicology Studies 35 Jan 21, 2015: USA Patent For Midkine To Treat Heart Failure 36 Jul 15, 2014: Cellmid Granted UK Patent for Use of Midkine for Hair Growth 37 Oct 06, 2011: Cellmid Completes Humanization Of Anti-midkine Antibody In Collaboration With Antitope 37 Appendix 39 Methodology 39 Coverage 39 Secondary Research 39 Primary Research 39 Expert Panel Validation 39 Contact Us 39 Disclaimer 40
List of Tables
Number of Products under Development for, H2 2016 7 Number of Products under Development by Therapy Area, H2 2016 8 Number of Products under Development by Indication, H2 2016 9 Comparative Analysis by Early Stage Products, H2 2016 10 Number of Products under Development by Companies, H2 2016 11 Products under Development by Companies, H2 2016 12 Number of Products under Investigation by Universities/Institutes, H2 2016 13 Products under Investigation by Universities/Institutes, H2 2016 14 Assessment by Monotherapy/Combination Products, H2 2016 15 Number of Products by Stage and Mechanism of Action, H2 2016 16 Number of Products by Stage and Molecule Type, H2 2016 18 Pipeline by Cellmid Limited, H2 2016 19 Pipeline by Ribomic Inc., H2 2016 20 Dormant Projects, H2 2016 32
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
